IgE-mediated anaphylaxis to Thiomucase®, a mucopolyssacharidase: allergens and cross-reactivity
Article first published online: 21 MAR 2002
Volume 57, Issue 3, pages 254–257, March 2002
How to Cite
Caballero, T., Alonso, A., De Miguel, S., Martín-Esteban, M., Varga, B., Pascual, C. Y. and López-Serrano, M. C. (2002), IgE-mediated anaphylaxis to Thiomucase®, a mucopolyssacharidase: allergens and cross-reactivity. Allergy, 57: 254–257. doi: 10.1034/j.1398-9995.2002.03322.x
- Issue published online: 21 MAR 2002
- Article first published online: 21 MAR 2002
- Accepted for publication 11 October 2001
- Echinococcus granulosus;
Background: Thiomucase® is a mucopolysaccharidase obtained from ovine tissues mainly used to facilitate the diffusion of local anaesthetics and in the treatment of cellulitis. A patient with an anaphylaxis in relation to the intramuscular administration of Thiomucase® is reported.
Objective: To investigate Thiomucase® allergens and their possible relationship with dander allergens and animal albumins.
Material and methods: Skin prick tests (SPT) and serum-specific IgE were performed with Thiomucase® and danders. Thiomucase® SDS-PAGE immunoblotting was performed in order to study allergens. RAST/CAP inhibition and SDS-PAGE immunoblotting inhibition were carried out to study the cross-reactivity.
Results: Skin prick tests (SPT) were positive to Thiomucase®, animal dander (cat, dog, sheep, other), bovine serum albumin (BSA), and echinococcus. Specific IgE was also positive to Thiomucase®, animal dander (cat, dog, sheep, other), BSA and echinococcus. In the RAST-CAP inhibition assays BSA was nearly completely inhibited by Thiomucase®, Thiomucase® was partially inhibited by BSA and cat and Echinococcus granulosus was partially inhibited by sheep and Thiomucase®. In the Thiomucase® SDS-PAGE immunoblotting several proteins fixed IgE, ranging from 20 kDa to > 94 kDa, the strongest with 43 kDa. The IgE fixation to BSA, cat and sheep in the SDS-PAGE immunoblotting was completely inhibited by the preincubation of the serum with Thiomucase®.
Conclusions: An IgE-mediated anaphylaxis to Thiomucase® is documented. Multiple allergens are recognized in Thiomucase® by the patient serum, the main with 43 kDa. Partial cross-reactivity with BSA, cat dander and sheep dander is documented.